# Spanish pharmaceutical regulatory and industrial reforms > Live situation record from CLSTR: https://clstr.news/situations/spanish-pharmaceutical-regulatory-and-industrial-reforms > Updated: 2026-10-06T16:13:04.000Z. Sources: 13. Developments: 3. The Spanish pharmaceutical sector continues to navigate regulatory reforms and efforts to bolster industrial competitiveness. Stakeholders have previously emphasized the need for reduced bureaucracy to counter Europe’s declining ability to compete with the United States and China. Recent developments show a push toward strengthening strategic autonomy. A resolution from the Joint Commission for Relations with the Court of Auditors, published in the Official State Gazette, has urged the government and the Ministry of Health to develop actions to reinforce healthcare autonomy. This includes a parliamentary recommendation to create a national reserve of essential medicines and medical products to manage extraordinary scenarios. However, the specific size, included medications, minimum inventory levels, and administration mechanisms for this reserve have not yet been established. The resolution also calls for improved interoperability of information systems to better track hospital beds, doctors, and nursing staff. Regarding drug pricing, the Ministry of Health has updated the reference pricing system for the National Health System for 2026. This update introduces 26 new reference sets—15 for pharmacy-dispensed prescription drugs and 11 for hospital use—to control pharmaceutical spending and ensure economic sustainability. The measure involves price revisions and the removal of sets that no longer meet regulatory requirements. ## Claims - European pharmaceutical reforms, including the Critical Medicines Act and Biotech Act, aim to strengthen Europe's industrial and productive capacities. (corroborated by 2 sources) - The pharmaceutical framework in Europe and Spain is undergoing simultaneous transformation. (corroborated by 2 sources) - Drug shortages in Spain are a complex and global problem despite recent improvements. (single source) - Recent data shows a favorable evolution in high-impact drug shortage scenarios. (single source) ## Timeline ### 2026-10-06: Spain proposes national medicine reserve and updates drug pricing Spain is planning a national reserve of essential medicines for emergencies and has updated its pharmaceutical reference pricing system to ensure healthcare sustainability. 5 sources. https://clstr.news/cluster/spain-proposes-national-medicine-reserve-and-updates-drug-pricing ### 2026-09-16: Spain addresses drug shortages and pharmaceutical regulatory reforms Experts discuss drug shortages and pharmaceutical regulatory reforms in Spain and Europe, focusing on industrial capacity and the Critical Medicines Act. 3 sources. https://clstr.news/cluster/spain-addresses-drug-shortages-and-pharmaceutical-regulatory-reforms ### 2026-09-07: Spanish pharmaceutical industry seeks regulatory agility to compete globally Spanish health officials and pharmaceutical leaders discuss regulatory coordination and the need to reduce bureaucracy to maintain European competitiveness against the US and China. 6 sources. https://clstr.news/cluster/spanish-pharmaceutical-industry-seeks-regulatory-agility-to-compete-globally --- Cite as: Spanish pharmaceutical regulatory and industrial reforms. CLSTR, https://clstr.news/situations/spanish-pharmaceutical-regulatory-and-industrial-reforms